Great insight Dr. Prasad. I agree that it is bizarre to pull a drug that works in the second-line/subsequent setting. Fortunately, we still have Acalabrutinib and Zanubrutinib - and I doubt NCCN changes their stance on Ibrutinib since it was already moved to "other recommended" last year.
Great insight Dr. Prasad. I agree that it is bizarre to pull a drug that works in the second-line/subsequent setting. Fortunately, we still have Acalabrutinib and Zanubrutinib - and I doubt NCCN changes their stance on Ibrutinib since it was already moved to "other recommended" last year.